Archive for the ‘Vermillion Inc. VRML’ Category

Vermillion, Inc. (VRML) Appoints Bruce Huebner as Interim CEO

Wednesday, November 28th, 2012

Vermillion, a molecular diagnostics company, announced that director Bruce A. Huebner has been appointed as interim CEO. He is following Gail S. Page, the company’s most recent CEO, who will assist in the transition and serve as a strategic advisor. Mr. Huebner will continue to serve on the board of directors as he assumes his new role.

Mr. Huebner has executive management experience in multiple clinical diagnostic companies, including Osmetech Molecular Diagnostics, Nanogen, and Gen-Probe. While serving as president of Osmetech, he successfully established the company as a fully integrated business, obtaining FDA clearance for four molecular diagnostic microarray products and introducing them to the marketplace. Huebner was also president and COO of Nanogen, a publicly held nanotechnology and microarray company.

Prior to Nanogen, Mr. Huebner was executive vice president and COO of Gen-Probe, a global leader in the development of nucleic acid tests. In less than 10 years, he grew Gen-Probe’s annual revenues from $42 million to a run-rate of more than $150 million. Huebner is currently a managing director of LynxCom Partners, a healthcare consulting firm with a focus on cancer diagnostics and personalized medicine.

“With more than 37 years of diagnostic industry experience and leadership, as well as serving on a special Vermillion board committee that evaluates marketing strategies for OVA1, Bruce will provide seasoned leadership as our interim CEO,” said James S. Burns, the company’s chairman of the board. “He will actively manage the business and ensure continuity of operations, as our succession committee searches for a new CEO who will take the company to its next level of growth and development.

Burns continued, “I would also like to thank Gail for the leadership and dedication that she has provided in bringing OVA1 to market and a pipeline of products to improve women’s health. We look forward to consulting with Gail in the coming months as we continue to build advocacy for our ovarian cancer franchise among gynecologists and women’s health groups.”

For more information, visit www.vermillion.com

Let us hear your thoughts below:

Dutton Associates Featured Company: Vermillion Inc. (VRML)

Friday, June 6th, 2008

Vermillion Incorporated has one goal: to develop and produce diagnostic tests that help physicians diagnose, select appropriate treatments and improve outcomes for patients. Vermillion develops clinical protein biomarker diagnostic products and services for use in the fields of oncology, hematology, cardiology, and women’s health. The company has several working relationships with academic and research institutes for the discovery and development of new products.

Vermillion applies a three-step approach when looking for a new solution to an existing problem. They first acquire information about the disease; this is done by applying a multi-biomarker approach to identify associations between genes, proteins and diseases that translate into meaningful information about disease states. Once this information is acquired Vermillion conducts multi-institutional studies, including clinically relevant controls, and partitioning of training from validation data to find the results. Finally Vermillion then uses this information to create and commercialize high-value diagnostic tests intended to help physicians perform quicker and more accurate tests.

Since 2005 Vermillion Incorporated has had an important strategic alliance with Quest Diagnostics. The partnership helps with the commercialization of protein biomarker diagnostic tests. Quest’s partnership is also focused on the development and commercialization of three diagnostic tests chosen from Vermillion’s pipeline. To date, Quest has chosen two of Vermillion’s tests for development: the ovarian tumor triage (OTT) test and the peripheral artery disease (PAD) test.

Let us hear your thoughts: Vermillion Inc. Message Board

OTCPicks Featured Company: Vermillion, Inc. (VRML) Opens Series of Teleconferences

Monday, May 5th, 2008

Vermillion, Inc. (NASD: VRML) recently hosted a teleconference that featured keynote speaker John Cooke, M.D., Ph.D, Professor of Medicine at Stanford University. The teleconference focused on the company’s peripheral artery disease (PAD) diagnostic program and improvements that could be made to enhance the detection of the disease.

This teleconference was the first in a series of future roundtable discussions, and served as an educational means to explain the current state of PAD and the clinical need for a blood test that can determine a person’s risk of developing the disease. PAD affects between 8 and 12 million Americans, and can double a person’s risk of heart attack or stroke, as well as increasing the risk of potential limb amputation or death. There are treatments available to save lives and limbs once the disease is diagnosed.

“The signs and symptoms of PAD often go unnoticed, and as a result many patients are not being properly diagnosed. We are in serious need of new, innovative tools to aid in the diagnosis and management of this life- threatening condition,” Dr. Cooke clarified. “Together with Vermillion, we are working to develop a simple blood test that will stratify an individual’s risk of developing PAD. This will serve as an important advancement in the overall management of the disease – benefiting both the patient and the physician alike.”

“Improving diagnosis of PAD, expediting treatment and enhancing patient outcomes is a key goal for Vermillion, as well as for Dr. Cooke and his research team at Stanford. We believe that our PAD diagnostic program will achieve these goals, and look forward to reporting additional clinical and commercial results in the coming months,” stated Gail Page, CEO and President of Vermillion.

Vermillion, Inc. has been active in the development, discovery, and commercialization of diagnostic tests that have been helping physicians diagnose and treat patients since 1993. The company has continued to develop clinical protein biomarker diagnostic products which are used in the fields of oncology, hematology, cardiology, and women’s health, primarily focusing on ovarian cancer. Over their years, the company has collaborated with nationally recognized academic and research institutions throughout the United States. At the closing of Friday’s trading, the company’s stock saw a rise of 39.66%.

Let us hear your thoughts below: